Legal Representation
Attorney
David Toren
USPTO Deadlines
Application History
26 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Dec 21, 2007 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Dec 20, 2007 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
May 14, 2007 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
May 14, 2007 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
May 14, 2007 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
Dec 14, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Dec 14, 2006 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
Dec 14, 2006 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
Jul 5, 2006 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Jun 7, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Jun 7, 2006 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
Jun 7, 2006 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
Jun 1, 2006 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Apr 12, 2006 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
Nov 28, 2005 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Nov 28, 2005 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Nov 28, 2005 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Jun 9, 2005 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Jun 9, 2005 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Jun 9, 2005 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Dec 14, 2004 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Sep 21, 2004 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Sep 1, 2004 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
Jun 29, 2004 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jun 29, 2004 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jan 6, 2004 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cardiovascular diseases including hyperlipidemia, atherosclerosis, myocardial infarction, angina pectoris and stroke
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005